Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 SEP 21 ... 2005 under a collaboration agreement pursuant to which they have been jointly developing daclizumab for the treatment of relapsing multiple sclerosis and volociximab (M200) for the ...
2009 NOV 2 ... of Facet as desirable but not a 'must have'. We already own a 50% interest in daclizumab, the drug Biogen Idec is jointly developing with Facet Biotech for the treatment of ...
2009 SEP 21 ... 2005 under a collaboration agreement pursuant to which they have been jointly developing daclizumab for the treatment of relapsing multiple sclerosis and volociximab (M200) for the ...
2009 AUG 31 ... "The Symphony study showed that at 1 year posttransplant, a regimen based on daclizumab induction, 2 g mycophenolate mofetil (MMF), low-dose tacrolimus and steroids resulted in ...
2009 OCT 19 ... CNI were converted to MMF and received a single dose of IL-2-receptor blocking antibody (Daclizumab). Control patients (n=8) continued CNI treatment. Renal function rapidly and ...
2009 OCT 12 ... cyclosporine, OKT3, mycophenolate mofetil, tacrolimus, azathioprine, and basiliximab or daclizumab. The incidence of nonskin tumors was 4.07%. Mean age at diagnosis was 61.41 years, mean ...
2009 JUN 15 ... diagnosed GBM will be presented. In this study, CDX-110 was given in combination with daclizumab, an antibody that blocks suppressive T cells, to determine whether this combination ...
2009 AUG 10 ... patients received standard-dose cyclosporine, MMF 2 g/day and corticosteroids, or daclizumab induction, MMF 2 g/day and corticosteroids plus low-dose cyclosporine, low-dose ...
2009 NOV 2 ... value of 90% and a negative predictive value of 71%. In normal volunteers, basiliximab, daclizumab, and AG490 achieved an equivalent augmentation of CD4(+) cell suppression in combination ...
2009 JUL 20 ... to a study from Brussels, Belgium, "Nondepleting anti-CD25 monoclonal antibodies (daclizumab) and depleting polyclonal antithymocyte globulin (Thymoglobulin) both prevent acute ...
2009 MAY 25 ... outcomes of patients with recalcitrant ocular inflammation treated with intravenous daclizumab. Retrospective case-series. Seventeen patients (33 eyes) with ocular inflammation who ...
2009 NOV 9 ... no significant differences between the results of induction therapy with basiliximab and daclizumab." Naderi and colleagues published the results of their research in ...
2009 JUN 15 ... CNI were converted to MMF and received a single dose of IL-2-receptor blocking antibody (Daclizumab). Control patients (n=8) continued CNI treatment. Renal function rapidly and ...
2009 JUN 1 ... "Several questions arise concerning the use of the anti-CD25 antibody daclizumab to treat multiple sclerosis (MS). To answer the following 3 questions related to the ...
2009 AUG 3 ... health care center were prospectively studied. Induction therapy included 2 doses of daclizumab and maintenance tacrolimus (n = 42) or cyclosporine (n = 29), mycophenolate mofetil and ...
2009 JUN 29 ... to standard-dose cyclosporine A (CsA), mycophenolate mofetil, and corticosteroids or daclizumab induction, mycophenolate mofetil, and corticosteroids with a low dose of CsA, tacrolimus ...
2009 NOV 9 ... "This study was designed to evaluate the impact of daclizumab monoclonal antibody on early and late kidney graft survival. From 2007 to 2008, 57 ...
